Antiretroviral/anti hiv (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 265 | Lipodystrophy | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04340388 (ClinicalTrials.gov) | June 2020 | 1/4/2020 | Contribution of Dolutegravir to Obesity and Cardiovascular Disease | Contribution of the Integrase Inhibitor Dolutegravir to Obesity and Cardiovascular Disease in Persons Living With HIV | HIV-1-infection;Antiviral Drug Adverse Reaction;Vascular Diseases;Cardiovascular Abnormalities;Abnormality of Adipose Tissue;Body Weight Changes;Body Fat Disorder;HIV-Associated Lipodystrophy Syndrome | Drug: Dolutegravir 50 MG;Drug: Antiretroviral/Anti HIV | Augusta University | NULL | Not yet recruiting | 18 Years | 100 Years | All | 30 | Phase 4 | NULL |